Top Markets
#1 CoW Protocol CoW Protocol +59.73%
#2 EXOD EXOD +56.80%
#3 Glidr Glidr +39.17%
#4 Cysic Cysic +31.67%
#5 Walrus Walrus +25.40%
#6 Humanity Humanity +22.30%
#7 Enso Enso +17.07%
#8 Velvet Velvet +17.00%
#9 Tutorial Tutorial +16.94%
#10 Huma Finance Huma Finance +14.02%
Coin of the day
CoW Protocol CoW Protocol
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Clasificación en acciones #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Precio por acción
$0.6
Última sincronización: 2024-08-14
Capitalización bursátil
$2.09M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
SG
Comercio ASLAN Pharmaceuticals Limited (ASLN)

Categoría

Healthcare
Ratio P/B de ASLAN Pharmaceuticals Limited (ASLN)
Ratio P/B al August 2026 TTM: -0.19
Según los informes financieros más recientes y el precio de las acciones de ASLAN Pharmaceuticals Limited, el ratio P/B actual (TTM) es -0.19. Al final de 2022, el ratio P/B era 0.96.
Historial del ratio P/B de ASLAN Pharmaceuticals Limited desde 2014 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) -0.19 -11.57%
2023 -0.21 -121.55%
2022 0.96 135.76%
2021 0.41 -118.92%
2020 -2.15 -82.88%
2019 -12.58 -1,216.28%
2018 1.13 -10.51%
2017 1.26 11.69%
2016 1.13 -308.68%
2015 -0.54 496.91%
2014 -0.09 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -3,515.13%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -3,460.96%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -1,963.87%
BE